Dimension Therapeutics
develops and commercializes gene therapeutics for the treatment of hemophilia and metabolic diseases... Read moreDimension Therapeutics
develops and commercializes gene therapeutics for the treatment of hemophilia and metabolic diseases... Read more
News
Nov 10, 2018
BioPortfolio
Dimension Therapeutics: Dimension Therapeutics Inc DMTX Financial and Strategic SWOT Analysis Review Report Updated 28092018 Prices from USD $300
Aug 14, 2018
BioPortfolio
Dimension Therapeutics: Dimension Therapeutics Inc DMTX Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 16042018 Prices from USD $250
Jun 16, 2018
BioCentury
Dimension Therapeutics: MANAGEMENT TRACKS
Nov 07, 2017
Benzinga
Dimension Therapeutics: Ultragenyx Completes Tender Offer and Acquisition of Dimension Therapeutics
Nov 03, 2017
4-traders
Dimension Therapeutics: Rigrodsky & Long, P.A. Files Class Action Suit Against Premara Financial, Inc.
Oct 26, 2017
PharmiWeb
Dimension Therapeutics: Ultragenyx and Dimension Announce Expiration of Hart-Scott-Rodino Waiting Period for Ultragenyx's Acquisition of Dimension
Oct 16, 2017
Proactive Investors
Dimension Therapeutics: Silence Therapeutics announces appointment of Dimension Therapeutics CEO as its non-executive chair
Oct 16, 2017
BioPortfolio
Dimension Therapeutics: Dimension Therapeutics Inc DMTX Financial and Strategic SWOT Analysis Review Report Updated 13092017 Prices from USD $125
Oct 13, 2017
4-traders
Dimension Therapeutics: Dimension Therapeutics Inc : SHAREHOLDER UPDATE: Brodsky & Smith, LLC Announces an Investigation of Dimension Therapeutics, Inc. - DMTX
Oct 13, 2017
4-traders
Dimension Therapeutics: WEISSLAW LLP: Dimension Therapeutics, Inc. Acquisition May Not Be in the Best Interests of DMTX Shareholders
